Regeneron (REGN) has been etching a flat base in the past few weeks, while also finding support at its 10-week moving average. The biotech sports an IBD Composite Rating of 97 out of a best-possible 99, reflecting its many strengths. But the company is a turnaround play, so you won't find an impressive earnings history. Regeneron Pharmaceuticals had been losing money for years until sales began to take off for its eye drug Eylea. Credit Suisse